Background-Elevated circulating levels of fetuin-A in blood have been associated with increased risk of cardiovascular disease. The goal of our study was to prospectively investigate the potential causal nature of the association between fetuin-A levels and myocardial infarction (MI) and ischemic stroke by applying a Mendelian randomization approach. Methods and Results-Five tagging single-nucleotide polymorphisms (rs2248690, rs2070633, rs2070635, rs4917, and rs6787344) capturing the common genetic variation of the fetuin-A coding gene ␣ 2 -Heremans-Schmid glycoprotein (AHSG) were genotyped in a case-cohort comprising 214 MI cases, 154 ischemic stroke cases, and 2152 persons who remained free of cardiovascular disease events in the European Prospective Investigation into Cancer and NutritionPotsdam study. One single-nucleotide polymorphism (rs6787344) was discarded because of Hardy-Weinberg disequilibrium. All AHSG tagging single-nucleotide polymorphisms were associated with fetuin-A plasma levels (PϽ0.0001). AHSG rs4917 CϾT showed the strongest association, explaining 21.2% of the phenotypic variance independent of potential confounding factors (ϩ35.5 g/mL increase per C-allele, Pϭ2ϫ10
Nutrition (EPIC)-Potsdam study suggests a strong link between high circulating fetuin-A levels and risk of cardiovascular disease (CVD): fetuin-A plasma levels were associated with incident myocardial infarction (MI) and ischemic stroke (IS) independent of established risk factors for CVD. 14 In support of this finding, fetuin-A levels correlated positively with intima media thickness of the common carotid artery, an early marker of atherosclerosis, in a clinical study. 15 Furthermore, findings from animal in vivo and human adipocyte in vitro studies suggest a direct effect of fetuin-A on the induction of subclinical inflammation and cytokine expression. 16 Thus, fetuin-A is believed to be directly involved in the pathogenesis of CVD.
However, it cannot be excluded that the observed relationship between fetuin-A levels and CVD risk is due to reverse causation or confounding, ie, that fetuin-A constitutes a marker of yet unknown metabolic processes. Evidence for a causal role of circulating fetuin-A in the pathogenesis of CVD can be generated by applying the concept of Mendelian randomization. 17 The Mendelian randomization approach assumes that any factor that possibly confounds a true association between an intermediate phenotype (eg, fetuin-A blood levels) and a disease (eg, CVD) is distributed evenly among those who carry and those who do not carry a predisposing genotype for the intermediate phenotype (high fetuin-A levels predicting alleles). Therefore, carriage of an allele or haplotype that exposes individuals to long-term elevated circulating fetuin-A should be associated with disease risk proportionally to the difference in circulating fetuin-A, attributable to the genetic variant.
In this study, we determined 4 tagging (tag) single-nucleotide polymorphisms (SNPs) of the fetuin-A gene (AHSG) and examined the hypothesis that AHSG heterogeneity is directly related to CVD risk due to changes in fetuin-A blood levels.
Methods

Study Population
The EPIC-Potsdam study is part of the multicenter prospective cohort study EPIC that involves over half a million people from 10 European countries. In Potsdam, Germany, 27 548 subjects, mainly aged 35 to 65 years, from the general population were recruited between 1994 and 1998. 18 The baseline examination included anthropometric and blood pressure measurements, blood sampling, a self-administered validated food-frequency questionnaire, and a personal interview on lifestyle habits and medical history. 19, 20 Follow-up questionnaires have been administered every 2 to 3 years to obtain information on current medication and newly developed diseases, including CVDs. 21 Informed consent was obtained from all study participants, and approval was given by the Ethical Committee of the State of Brandenburg, Germany.
The association of AHSG tagSNPs with risk of MI and IS was analyzed using a case-cohort design 22 using EPIC-Potsdam data from the study population previously described. 14 The study population included a random sample of 2500 subjects (subcohort) and all newly arisen MI and IS cases from the EPIC-Potsdam cohort verified in each follow-up round until November 30, 2006 . Two hundred sixty-nine incident MI and 199 incident IS cases were confirmed during a mean follow-up time of 8.2Ϯ2.2 years in the EPIC-Potsdam cohort. If both events occurred in an individual, only the first event was considered. After exclusion of participants with a history of MI or IS at baseline, with missing covariate assessment, fetuin-A blood concentration, AHSG genotypes, and fully obtained follow-up data, the case cohort comprised 2520 individuals (214 MI cases, 154 IS cases, and 2152 noncases). In agreement with the case-cohort design, 23 45 incident cases (22 MI cases and 23 IS cases) belonged to the subcohort (nϭ2197). The subcohort was used to investigate the association between AHSG alleles/haplotypes and fetuin-A plasma levels.
Ascertainment of Incident MI and Stroke
Potential cases of incident MI or stroke were identified by self-report in 1 of the 4 follow-up questionnaires, or by death certificate. To increase sensitivity, the questionnaire included additional questions about typical stroke symptoms. 24 All self-reports for CVD incidences were verified by contacting the patients' attending physicians or by review of death certificates according to World Health Organization Monitoring Trends Determinants in Cardiovascular Disease criteria. 25 According to ICD-10, 26 cases were classified as incident MI (ICD-10 I21), IS (ICD-10 I63.0-I63.9), intracerebral (ICD-10 I61.0-I61.9) or subarachnoidal hemorrhage (ICD-10 I60.0-I60.9), or undetermined stroke (ICD-10 I64.0-I64.9) by 2 physicians in the study center.
Biochemical and Genetic Analyses
Plasma levels of fetuin-A, total cholesterol, high-density lipoproteincholesterol, triglycerides, high-sensitivity C-reactive protein, creatinine, and ␥-glutamyltransferase were measured with the automatic ADVIA 1650 analyzer (Siemens Medical Solutions, Erlangen, Germany). Glomerular filtration rate was estimated from plasma creatinine levels by using the prediction equation described by Levey et al. 27 For determination of fetuin-A, an immunoturbidimetric method was used with specific polyclonal goat antihuman fetuin-A antibodies to human fetuin-A (BioVendor Laboratory Medicine, Modreci, Czech Republic). This method was evaluated in a side-byside comparison with an ELISA (intra-assay CV 3.5% and interassay CV 5.4%, BioVendor) showing a correlation of rϭ0.93.
Five tagSNPs (rs2248690, rs2070633, rs2070635, rs4917, and rs4831) were identified in the HapMap 22/phaseII CEPH (Utah residents with ancestry from northern and western Europe) population data 28 using stringent criteria (minor allele frequency Ͼ0.05 and pairwise r 2 Ն0.8) according to Tagger software 29 implemented in Haploview program. 30 The tagged gene region comprised 10.6 kb of chromosome 3, position 187811624 to 187822224, including 2000 bp 5Ј-flanking and 345 bp 3Ј-flanking sequences of the AHSG gene. The positions of the selected tagSNPs are illustrated in Figure 1A . SNP rs4831 has been reported previously to have failed TaqMan analysis. 31 Therefore, the 3Ј-flanking SNP rs6787344 was chosen as surrogate for rs4831 because both SNPs showed strong linkage disequilibrium (r 2 ϭ0.84). Genotyping of whole-genome-amplified DNA samples was performed with the TaqMan System (Applied Biosystems, Foster City, Calif) using 5 ng of DNA. The average genotyping success rate in the 5 SNPs was Ͼ98%.
Statistical Analysis
Linkage disequilibrium between SNPs was calculated by determination of the squared correlation coefficient r 2 and Lewontin's DЈ. 32 Haplotype frequencies were estimated by the expectationmaximization algorithm. Based on haplotype trend regression analysis described by Zaykin et al, 33 individual haplotypes were estimated, including all AHSG haplotypes with frequencies Ͼ2%. Analysis of covariance considering an additive genetic model was used to assess the association between genotypes or haplotypes and fetuin-A levels. SNPs were coded according to the direction of association with fetuin-A plasma level: rs2248690 (TTϭ0, ATϭ1, and AAϭ2), rs2070633 (TTϭ0, CTϭ1, and CCϭ2), rs2070635 (AAϭ0, AGϭ1, and GGϭ2), rs4917 (TTϭ0, CTϭ1, and CCϭ2). Haplotype analysis was restricted to individuals with a probability of 100% for either no copy or 2 copies present or a probability of 49% to 50% for the presence of 1 copy of the respected haplotype. The haplotype-specific effect was estimated as the difference of the means in fetuin-A between carriers of 1 or 2 copies of a haplotype compared with those without the haplotype. Candidate covariates were selected by stepwise logistic regression with age and sex forced into the multivariable model.
Association of single AHSG SNPs with risk of MI and IS and combined CVD endpoints were calculated as hazard rate ratios (RR) with 95% CI using Cox proportional-hazard regression, modified according to the Prentice method 23 to account for the case-cohort design and using a robust estimator for CI. Age was the underlying time variable in the counting processes, with entry defined as the subjects' age at the time of recruitment and exit defined as age at the diagnosis of MI and IS, respectively, or censoring. The statistical models were adjusted for sex and potential confounding and effect modifying factors according to previous analyses and candidate covariate selection (cigarette smoking, history of diabetes, history of hypertension, total cholesterol, high-density lipoprotein-cholesterol, C-reactive protein level, physical activity, body mass index, waist circumference, alcohol intake, and educational attainment). Smoking status was defined as "never smoker," "former smoker," "Ͻ20 cigarettes per day," or "Ն20 cigarettes per day." Physical activity was calculated from mean time spent on sporting activities during summer and winter seasons (h/wk) and categorized as "Ͻ2 h/wk," and "Ն2 h/wk." Alcohol intake comprised 3 categories specified for each gender (men: "Ͻ2 g/d," "2 to 15 g/d," "Ͼ15 g/d"; women: "Ͻ1 g/d," "1 to 7.5 g/d," "Ͼ7.5 g/d"). Educational attainment was classified as "vocational school or less," "technical school," and "university degree." Prevalent hypertension was defined as systolic blood pressure Ն140 mm Hg or diastolic blood pressure Ն90 mm Hg or self-reporting of a diagnosis or of use of antihypertensive medication. The prevalence of diabetes at baseline was evaluated by a physician using information on self-reported medical diagnosis, medication records, and dieting behavior. In ambiguous cases, the diagnosis was confirmed by personal communication with the participant and/or treating physician.
A comparison was performed between the risk estimates of multivariable adjusted models with and without additionally included fetuin-A plasma concentration (continuous variable) using the method described by Hoffmann et al. 34 Based on the assumption of random allocation of the AHSG alleles by conception and given the effect of the genotype (allele-dose effect) on the phenotype and the estimate of the genotype (allele)-disease association, we estimated the unconfounded size of the effect of the phenotype on the disease using the calculation given by Minelli et al 35 for Mendelian randomization meta-analysis approaches. The statistical analyses were performed with SAS release 9.1 (SAS Institute, Cary, NC). The power for detecting an association between AHSG polymorphisms and MI, IS, and both disease endpoints was calculated using Quanto (http://hydra.usc.edu/GxE/), 36 concerning a log-additive model, a desirable power Ͼ80%, ␣ϭ0.05, and a disease prevalence of 2% (supplemental Table I ).
Results
The genomic positions of the AHSG tagSNPs are shown in Figure 1A . The genotype distribution of SNP rs6787344 did not follow Hardy-Weinberg law (PϽ0.0001), and therefore the polymorphism was excluded from further analysis. Linkage disequilibrium between each pair of tagSNPs ranged between r 2 ϭ0.23 to 0.71 and DЈϭ0.88 to 1.0 ( Figure 1B ). We first examined the relations between each of the 4 tagSNPs at the AHSG locus and fetuin-A levels. Baseline fetuin-A data were used from 2197 middle-aged persons. Details of the study population are given in Table 1 . Independent determinants of fetuin-A levels were identified from stepwise regression of 21 baseline factors (Supplemental Table II ). Total cholesterol, high-sensitivity C-reactive protein, ␥-glutamyltransferase, and waist circumference were positively associated with fetuin-A. Age, high alcohol intake, and plasma triglycerides showed an inverse association with fetuin-A. The baseline factors explained 6.3% of the interindividual variability in plasma fetuin-A level. We then used multivariable adjusted linear regression models sizing the effect of AHSG tagSNP alleles associated with high fetuin-A. All 4 SNPs were independently related to fetuin-A (PϽ0.0001) with minor changes in the effect sizes when adjusted for sex and age only ( Table 2) . AHSG SNP rs4917 showed the strongest association with fetuin-A concentrations (ϩ35.5 g/mL per C-allele, Pϭ2ϫ10 Ϫ121 ). The polymorphism explained as much as 21.2% of total plasma fetuin-A variation (Table 2) .
Mean plasma fetuin-A levels differed also across 5 common haplotypes of AHSG (order of SNPs: rs2248690 AϾT, rs2070633 CϾT, rs2070635 AϾG, rs4917 CϾT). The most prevalent haplotype A-C-G-C (frequency, 44%), harboring the major alleles of SNPs rs2248690, rs2070633, and rs4917, was associated with increased fetuin-A levels (ϩ27.5 g/mL per copy, PϽ0.0001). Haplotype T-T-A-T (frequency, 24%) characterized by 3 minor SNP alleles showed an inverse association with fetuin-A levels (Ϫ35.2 g/mL per copy, Pϭ6.7ϫ10 Ϫ98 ). Three other, low-frequency (8%, 9%, and 13%) haplotypes (A-C-A-C, A-T-A-T, and A-T-A-C) were also associated with fetuin-A (Pϭ0.02 to PϽ0.0001 per copy). All analyses were multivariable adjusted according to the single SNP analyses.
We then determined the association of AHSG tagSNPs with risk of CVD endpoints (MI and IS). The characteristics of the case-cohort study subjects are described in Table 1 . Disease risks were evaluated in 214 incident MI and 154 incident IS cases and 2152 persons who have remained free of 
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CVD during follow-up. In multivariable adjusted models, similar hazard rate ratios were found for all AHSG tagSNPs ( Table 3 ). The AHSG SNP rs4917 C-allele was associated with a 1. On the basis of the assumption underlying Mendelian randomization, we calculated the size of the effect of 1 SD (52.1 g/mL) change in fetuin-A levels on MI by combining the estimates obtained from the association of the AHSG SNP rs4917 C-allele with risk of MI (RR, 1.34 [95% CI 1.05 to 1.70]) and the association of the C-allele with fetuin-A levels (35.5 g/mL difference per allele), that resulted in a theoretically predicted MI risk of 1.54-fold for 1 SD change in fetuin-A (Figure 2) .
Discussion
This report is the first to provide evidence for a putative causal nature of the association between elevated fetuin-A blood levels and MI. We used an instrumental variable method to evaluate the potential causal relationship between elevated circulating fetuin-A and future risk of MI or IS implied from Mendelian randomization. 17 Mendelian randomization involves comparison of phenotype and genotype effects in observational studies. If the association between a modifiable risk factor and disease is causal, the genetic variant associated with this risk factor should be related to the disease outcome to the extent predicted by the magnitude of its association with the risk factor. The imputed estimate is likely to be equivalent with the direct estimate from an observational study provided that a very high degree of precision can be assumed for all 3 estimates. 35 Our imputed estimate suggested that the effect of 1 SD change in circulating fetuin-A (fetuin-A levels in healthy individuals averaged at about 228 g/mL with 1 SDϭ52 g/mL) on disease risk leads to an increase of 54% in the risk of MI, which is comparable with the observed association between circulating fetuin-A and MI in our previous study (risk increase 59%). 14 This study provided a high accuracy of the association between genotype (AHSG rs4917 C-allele) and phenotype (fetuin-A levels), because the association was established in a large population-based, ethnically homogenous sample and was controlled for other confounding factors.
Compared with other studies on genotype-phenotype relationships, eg, for blood proteins including plasminogen activator inhibitor 1, 37 monocyte chemoattractant protein 1, 38 and C-reactive protein, 39 in which SNPs in the gene encoding the respective blood protein explained, on average, 1% to 2.5% of the phenotypic variation, the contribution of AHSG SNPs on circulating fetuin-A found in our study (Ϸ21%) indicates a very strong relationship.
Our findings confirm previous reports that the common alleles of rs4917 and rs2248690 are associated with increased plasma fetuin-A levels. 40 -43 The AHSG rs2248690 (g.-799 A/T) polymorphism has been shown to change a transcription factor binding site in the 5Ј-flanking gene region and to alter fetuin-A expression levels in HepG2 cells. 42 Transcription factor AP-1, a corepressor, showed higher affinity to the rs2248690 T-coding sequence. Thus, a greater transcriptional repression of the gene might occur in hepatocytes of minor T-allele carriers, which would lead to lower circulating fetuin-A in T-allele carriers compared with A-allele carriers. The minor T-allele was associated with significantly lower fetuin-A levels in previous studies 42, 43 and in this report, giving support to a biological function of this mutation. The pivotal question, why we found concordant associations for all gene tagging polymorphisms, is difficult to answer. One hypothetical reason that could explain this phenomenon might be a closely related functional polymorphism that would show similar linkage with all tagSNPs. As a matter of fact, this variant would exert even a higher impact on fetuin-A plasma levels than those 4 tagSNPs investigated.
It is important to consider the potential limitations of our study. Our case-cohort study sample consisted of a modest number of incident CVD patients, and thus, the lack of association between others, with the exception of the AHSG rs4917 polymorphism and MI or IS or both CVD events, may be due to insufficient statistical power. Our estimates suggested that we had Ͼ80% power to detect an odds ratio of Ն1.25 per risk allele if we assumed an allele frequency of 45% or more. Studies with larger numbers of affected individuals would be more suitable to precisely assess the Means (95% CI) of fetuin-A (g/mL) adjusted for age, sex, C-reactive protein, triglycerides, total cholesterol, ␥-glutamyltransferase, high alcohol intake, and waist circumference; SNPs were coded according to the direction of their association with fetuin-A (minor alleles are in bold letters).
MAF indicates minor allele frequency; HWE, Hardy-Weinberg equilibrium; partial R 2 , the proportion of multivariable adjusted fetuin-A level explained by each SNP. Hazard rate ratios are given for the allele associated with a higher fetuin-A level 3 bold letters. Model 1, adjusted for age, sex, BMI, waist circumference, history of diabetes, history of hypertension, cigarette smoking, educational attainment, physical activity, total cholesterol (mg/dL), HDL-cholesterol (mg/dL), and C-reactive protein (mg/L); Model 2, adjusted as model 1 plus additional adjustment for fetuin-A (g/mL).
*Testing the hypothesis that hazard rate ratios in models 1 and 2 are equal.
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modest effect sizes of fetuin-A genetic variation on CVD endpoints. We have not accounted for multiple testing in this analysis. The Bonferroni correction would probably have been too conservative owing to the high degree of correlation among the tests performed. However, the associations of AHSG tagSNPs and haplotypes with fetuin-A levels would have survived even a Bonferroni correction. In summary, our application of Mendelian randomization plausibly suggested a functional link between elevated fetuin-A plasma levels and MI risk. Thus, interventions to modify fetuin-A levels might be expected to influence disease risk.
